Effects of protein coding polymorphisms in the kallikrein 1 gene on baseline blood pressure and antihypertensive response to irbesartan in Chinese hypertensive patients

Journal of Human Hypertension

Volumn 25, Issue 5, 2011, Pages 327-333

  Jiang, S ^a,b   Hsu, Y H ^c,d   Venners, S A ^e   Zhang, Y ^b   Xing, H ^b   Wang, X ^f   Xu, X ^b,g  

^a ANHUI UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

essential hypertension; irbesartan; kallikrein 1; polymorphism; response

Indexed keywords

ADENINE; CYTOSINE; GLUTAMINE; GUANINE; IRBESARTAN; KALLIKREIN; LYSINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHINESE; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC CODE; GENOTYPE; HAPLOTYPE; HAPLOTYPE MAP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIPHENYL COMPOUNDS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TETRAZOLES; TISSUE KALLIKREINS;

EID: 79954891273     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.70     Document Type: Article

References (30)

1. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. NEngl J Med 1996; 334:1649-1654. (Pubitemid 126613653)
2. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31:1311-1316. (Pubitemid 28248833)
3. Pool JL, Guthrie RM, Littlejohn III TW, Raskin P, Shephard AM, Weber MA et al. Dose-related anti-hypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-470. (Pubitemid 28231459)
4. Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902. (Pubitemid 27526898)
5. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004; 64: 999-1028. (Pubitemid 38608479)
6. Jiang S, Mao G, Zhang S, Hong X, Tang G, Li Z et al. Individual and joint association of alpha1A-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjects. Clin Pharmacol Ther 2005; 78(3): 239-248. (Pubitemid 41254109)
7. Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC et al. The relationship between the plasma concentration of irbesartan and the antihyper-tensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens 2008; 21(7): 836-839. (Pubitemid 351913624)
8. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109(8): 1007-1009. (Pubitemid 34408574)
9. Zinner SH, Margolius HS, Rosner B, Kass EH. Stability of blood pressure rank and urinary kallikrein concen-tration in childhood: an eight-year follow-up. Circula-tion 1978; 58(5): 908-915. (Pubitemid 9042776)
10. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 13(1): 3-8. (Pubitemid 19047274)
11. Wang J, Xiong W, Yang Z, Davis T, Dewey MJ, Chao J et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994; 23(2): 236-243. (Pubitemid 24050287)
12. Wang C, Chao L, Chao J. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 1995; 95(4): 1710-1716.
13. Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP et al. A comprehensive nomenclature for serine proteases with homology to tissue kallik-reins. Biol Chem 2006; 387: 637-641. (Pubitemid 43964785)
14. Gan L, Lee I, Smith R, Argonza-Barrett R, Lei H, McCuaig J et al. Sequencing and expression analysis of the serine protease gene cluster located in chromo-some 19q13 region. Gene 2000; 257: 119-130.
15. Song Q, Chao J, Chao L. DNA polymorphisms in the 5?-flanking region of the human tissue kallikrein gene. Hum Genet 1997; 99(6): 727-734. (Pubitemid 27243749)
16. Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS et al. Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 2002; 61: 1030-1039. (Pubitemid 34175472)
17. Hua H, Zhou S, Liu Y, Wang Z, Wan C, Li H et al. Relationship between the regulatory region poly-morphism of human tissue kallikrein gene and essential hypertension. J Hum Hypertens 2005; 19: 715-721. (Pubitemid 43118095)
18. Rossi GP, Taddei S, Ghiadoni L, Virdis A, Zavattiero S, Favilla S et al. Tissue kallikrein gene polymorphisms induce no change in endotheliumdependent or in-dependent vasodilation in hypertensive and normo-tensive subjects. J Hypertens 2006; 24: 1955-1963. (Pubitemid 44371261)
19. Zhao W, Wang L, Lu X, Yang W, Huang J, Chen S et al. A coding polymorphism of the kallikrein 1 gene is associated with essential hypertension: a tagging SNP-based association study in a Chinese Han population. J Hypertens 2007; 25(9): 1821-1827. (Pubitemid 47356622)
20. Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 2005; 19: 1172-1174. (Pubitemid 40946455)
21. Messadi-Laribi E, Griol-Charhbili V, Pizard A, Vincent MP, Heudes D, Meneton P et al. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 2007; 323(1): 210-216. (Pubitemid 47443244)
22. 2 Livak KJ. Allelic discrimination using fluorogenic probes and the 50 nuclease assay. GenetAnal 1999; 14: 143-149. (Pubitemid 29095371)
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434. (Pubitemid 34112296)
24. Iwai N, Tago N, Yasui N, Kokubo Y, Inamoto N, Tomoike H et al. Genetic analysis of 22 candidate genes for hypertension in the Japanese population. J Hypertens 2004; 22: 1119-1126. (Pubitemid 38721003)
25. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotec-tive effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996; 27: 7-13. (Pubitemid 26017674)
26. Hong ZY, Zhang XQ, Huang G, Ling DJ, Xu XP Effects of human tissue kallikrein gene A1789G polymorph-ism on plasma creatinine levels in patients with essential hypertension. Chin J Clin Pharmacol Ther 2005; 10(6): 637-641.
27. Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13: 968-976. (Pubitemid 34274093)
28. Yousef GM, Diamandis EP The new human tissue kallikrein gene family: structure, function, and asso-ciation to disease. Endocr Rev 2001; 22: 184-204. (Pubitemid 32458158)
29. Rossi GP, Taddei S, Ghiadoni L, Virdis A, Zavattiero S, Favilla S et al. Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or inde-pendent vasodilation in hypertensive and normotensive subjects. J Hypertens 2006; 24(10): 1955-1963. (Pubitemid 44371261)
30. Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 2005; 115: 780-787. (Pubitemid 40322255)